GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.

GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...

GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it ...

China's health authority has granted GSK's Blenrep blood cancer treatment with a so-called 'Breakthrough Therapy Designation' ...

GSK's oncology R&D head. Abdullah joined GSK in 2019, after eight years at the oncology business of U.K. rival AstraZeneca, where he was vice president and global head of immuno-oncology.

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... This gap widens when we remove the impact of R&D which disproportionately impacts biotechnology companies, as for ...

GSK-3739937 is commercialized by GSK, with a leading Phase I program in Human Immunodeficiency Virus (HIV) Infections (AIDS).